Switching from Wegovy to Mounjaro

A Switch Needs a New Plan

Switching Wegovy to Mounjaro is a prescribing decision, rather than a pen exchange. Wegovy contains semaglutide and Mounjaro contains tirzepatide. They have different licensed instructions, and the dose printed on one pen cannot be converted into an equivalent dose of the other by matching numbers. Your current treatment history matters, but it does not replace a fresh assessment.

People consider changing medicines for different reasons. Side effects, practical difficulties, treatment response or a change in their circumstances may prompt a conversation. Start with the problem you want to solve. “I struggle to eat after my injection” and “I want to understand my options after a plateau” need different discussions, even if both lead to questions about switching.

The aim is a clear, written plan covering the last Wegovy injection, whether a switch is appropriate, the first Mounjaro dose and follow-up. This guide helps you prepare that conversation. It does not give a personal start date, washout interval or dose recommendation, and it should not be used to bridge prescriptions with leftover pens.

Understand the Reason for Changing

Before switching Wegovy to Mounjaro, review what has happened on Wegovy. How long have you used it? Which prescribed doses have you taken? Have you had gaps, troublesome symptoms or changes to other medicines? A clear history helps the prescriber distinguish a treatment problem from expectations that need adjusting.

If your main concern is slow progress, look at the pattern over time instead of comparing one week with another person’s experience. A weight-loss plateau is a reason for review, not proof that another injection is automatically needed. Ask what counts as a meaningful response in your situation and when that response will be assessed.

• Explain the main difficulty you hope a different treatment will address.
• Bring a record of prescribed doses and any missed treatment periods.
• Describe adverse effects, including whether they affected food or fluids.
• Say what has been practical or difficult about the current routine.

Be honest about prescriptions obtained elsewhere. The clinician needs an accurate starting point, including treatments you have already stopped. A list built from pharmacy labels is more useful than relying on memory or assuming that every pen with a similar appearance contains the same medicine.

Switching Wegovy to Mounjaro: Why Doses Differ

Milligrams describe the amount of a particular substance. They do not create a shared strength scale between semaglutide and tirzepatide. Taking a higher Wegovy dose does not establish which Mounjaro dose is safe for you. Likewise, a friend’s successful switch does not create a suitable instruction for another patient.

Clinical guidance on switching GLP-1 medicines highlights the limited evidence for switching between brands. Prescribers need to work with the relevant product information, clinical history and monitoring needs. A generic conversion chart can hide the uncertainty that should be discussed during a real consultation.

You can ask the clinician to explain the reasoning in plain English. For example: “How are you taking my previous treatment into account?” or “What will you check before increasing the new medicine?” These questions make the plan easier to understand without encouraging you to calculate a dose yourself.

Comparing the differences between Wegovy and Mounjaro can help frame your questions. However, a comparison article cannot confirm suitability, predict an individual result or replace a prescription. The decision should account for how you feel and your wider health, not only a headline about average weight loss.

Starting Doses Are Context, Not Switching Instructions

The licensed Mounjaro starting regimen is 2.5 mg once weekly, followed by 5 mg after four weeks. Further increases, when prescribed, are in 2.5 mg steps after at least four weeks on the current dose. The licensed dosing information for tirzepatide explains the regimen, but does not provide a universal Wegovy-to-Mounjaro conversion.

These details help you recognise that escalation is planned and gradual. They do not tell you to start treatment today or select a pen without assessment. The prescriber must confirm the actual dose, date, review arrangements and what to do if symptoms occur. A previous prescription for Wegovy does not automatically authorise a Mounjaro prescription.

• Check the medicine name and strength on your new prescription.
• Ask for the first administration date in writing.
• Confirm when the first review should happen and how to arrange it.
• Find out whom to contact before any proposed increase.

Do not take extra doses to speed up a switch or try to compensate for a gap. Avoid unofficial pen manipulation and dosing advice from social media. If the instructions on a label seem inconsistent with what you were told, resolve the discrepancy with the dispensing pharmacy before using the medicine.

Switching Wegovy to Mounjaro: Planning the Timing

There is no single switching interval that this article can safely assign to every patient. Semaglutide does not disappear as soon as the weekly injection day passes. Recent side effects, gaps in treatment, other medicines and the reason for switching can all influence the clinical decision.

The regulatory advice on changing GLP-1 treatment is to consult a healthcare professional before switching. Obtain a plan that explicitly names your last Wegovy date and proposed Mounjaro start. Do not overlap the medicines or add one while continuing the other unless a qualified prescriber has given a clinically appropriate, explicit instruction.

If a delivery is delayed or an appointment moves, contact the clinic to confirm what that means for the plan. Do not treat an old calendar entry as authority to restart after circumstances have changed. A treatment gap may require reassessment, including consideration of tolerability and the appropriate starting approach.

Administrative planning is useful too. Check that the prescription and review are arranged before you assume a new medicine will be available. This article does not confirm stock, prices or service turnaround times. Ask the provider for current information and record the response separately from the clinical dosing instructions.

A Switching Conversation Checklist

This table separates the information you can prepare from decisions that belong to the prescriber. It is designed to make the consultation more efficient, without turning the appointment into a request for a predetermined dose.

Keep the resulting instructions somewhere easy to find. If more than one service is involved, ask who owns the ongoing prescription and follow-up.

Side Effects Can Still Occur After a Switch

A new medicine may still cause digestive symptoms, even if you have previously used a weight-loss injection. Do not assume your previous experience guarantees an easy transition. Tell the team about symptoms that persist, worsen or interfere with eating, drinking or usual activities. Treatment tolerance is something to assess, rather than a test of determination.

Plan manageable meals, access to drinks and an opportunity to ask questions during the first weeks. Food choices when appetite changes can support practical planning. If nausea or vomiting becomes a barrier to adequate intake, a clinical review matters more than trying to perfect a menu.

• Note when a new symptom appears and how long it lasts.
• Record whether fluids stay down and urine output changes.
• Contact the prescriber before a planned increase if symptoms are troublesome.
• Use urgent services for severe or rapidly worsening problems.

Severe persistent abdominal pain, particularly towards the back, requires urgent assessment because pancreatitis is possible. Breathing difficulty or mouth or throat swelling may indicate a severe allergic reaction: call 999. Do not wait for the next routine review when symptoms suggest an emergency, and tell urgent services which medicines you have used.

Review Other Medicines and Contraception

Provide the whole medicine list, including prescriptions, pharmacy purchases and supplements. If you have diabetes, the prescriber may need to review treatment and monitoring. Do not reduce or stop insulin yourself. A weight-management switch should be coordinated with the team responsible for your diabetes care when those pathways overlap.

Oral contraception needs specific attention with Mounjaro. People using the pill should use a non-oral contraceptive method or add barrier protection for four weeks after starting tirzepatide and after each dose increase. Arrange this before the switch, and ask for advice tailored to the pill you take.

Avoid assuming that advice previously given for Wegovy transfers unchanged. Vomiting or severe diarrhoea can also affect pill protection, so the appropriate missed-pill guidance may be needed. If protection might have failed, seek prompt emergency contraception advice rather than waiting until the next weight-management appointment.

Pregnancy plans should also be discussed before any change. These medicines are not treatments for use during pregnancy. If you think you may be pregnant, contact your clinician promptly and follow their advice. Planning ahead is safer than attempting to work backwards from the date of the last injection.

Set Useful Expectations for Follow-Up

A review after switching Wegovy to Mounjaro should consider more than the number on the scales. Discuss whether you can eat appropriately, function normally and use the treatment as prescribed. Agree what information the clinician wants and how to report it. You should understand both the routine follow-up route and the route for an urgent concern.

Ask how response will be judged over time. Treatment timelines provide context, but an individual outcome remains uncertain. A switch should not come with a promise of faster loss, a fixed clothing size or a guarantee that side effects will disappear.

Make the Handover Clear

When switching Wegovy to Mounjaro, repeat the plan back in your own words before leaving the consultation. Name the medicine you are stopping, the medicine being considered, and the confirmed dates. If any part remains uncertain, ask for clarification. A clear instruction is more useful than a long explanation you cannot confidently apply at home.

• Confirm which clinician is responsible for your next prescription.
• Keep the written plan and contact route together.
• Tell the team about changes in health before your planned start.
• Check that follow-up remains booked after any administrative delay.

Your ordinary routine still matters. Support through treatment setbacks can help you maintain realistic expectations while decisions are reviewed. There is no need to present a switch as a fresh start that must work perfectly. Safe treatment includes being able to report difficulties, revisit the plan and make informed choices.

Consider the Treatment Choice

A switching decision should consider which weight-loss injection is appropriate for your circumstances, alongside the reason for changing. The most suitable plan remains an individual prescribing decision.